[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"figo-stage-iii-and-iv-ovarian-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:figo-stage-iii-and-iv-ovarian-cancer":57},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100054111",false,"NCT07322094","CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer","CATALINA-4: Phase 1B\u002F2 Study of TORL-1-23 With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Newly Diagnosed Patients With Advanced Stage Ovarian Cancer","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1\n* Histologically or cytologically confirmed diagnosis of epithelial ovarian, primary peritoneal or fallopian tubes cancer\n* FIGO Stage III or IV\n* Positive for claudin 6 (CLDN6) expression\n* Adequate organ function\n\nExclusion Criteria:\n\n* Clear cell, mucinous, sarcomatous, mixed histology, low-grade\u002Fborderline, or non-epithelial ovarian cancers\n* Prior systemic treatment for the disease under study\n* Prior surgery\n* Prior radiation therapy to the abdomen or pelvis\n* Current recipient or receipt within 5-half-lives of C1D1 of any of the following: chemotherapy, biologic\u002Ftargeted therapy, herbal medications or supplements, immunomodulator therapy for any disease indication.\n* History of noninfectious pneumonitis\u002Finterstitial lung disease (ILD) within 6 months of first dose of study drug.\n* Active, progressive, or symptomatic brain metastases\n* Participants considered poor medical risks due to serious, uncontrolled medical conditions, active infections, or nonmalignant systemic diseases\n* Pregnant or breastfeeding women","FEMALE","18 Years","75 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","A Phase 1B\u002F2 Study to Investigate the Safety and Efficacy of TORL-1-23 with Chemotherapy Given Before Initial Surgery in Women with Advanced Stage Ovarian Cancer",[27,28,29],"FIGO Stage III and IV Ovarian Cancer","Fallopian Tube Cancers","Primary Peritoneal Cancer","RECRUITING","2026-07-09",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2025-12-10",{"date":38,"type":20},"2028-01",{"name":40,"class":41},"TORL Biotherapeutics, LLC","INDUSTRY",7,{"id":44,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":48,"briefSummary":25,"conditions":49,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":53,"completionDateStruct":54,"leadSponsor":55,"locationsCount":56},"100617705","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.\n* Histologically or cytologically confirmed diagnosis of epithelial ovarian, primary peritoneal or fallopian tubes cancer\n* FIGO Stage III or IV\n* Positive for claudin 6 (CLDN6) expression\n* Adequate organ function\n\nExclusion Criteria:\n\n* Clear cell, mucinous, sarcomatous, mixed histology, low-grade\u002Fborderline, or non-epithelial ovarian cancers\n* Prior systemic treatment for the disease under study\n* Prior surgery\n* Prior radiation therapy to the abdomen or pelvis\n* Current recipient or receipt within 5-half-lives of C1D1 of chemotherapy, biologic\u002Ftargeted therapy, immunomodulator therapy for any disease indication\n* Active, progressive, or symptomatic brain metastases\n* Participants considered poor medical risks due to serious, uncontrolled medical conditions, active infections, or nonmalignant systemic diseases\n* Pregnant or breastfeeding women","70 Years",{"count":19,"type":20},[23,24],[27,28,29],"2026-01-05",{"date":52,"type":34},"2026-01-07",{"date":36,"type":34},{"date":38,"type":20},{"name":40,"class":41},1,""]